Cervical Cancer
Conditions
Interventions
Experimental Group:The experimental group received modified abdominal radical hysterectomy(MARH), with specific improvement steps as follows:
1. Operating position change: the patient took the improve
2. Improvement of vaginal amputation mode: clamp the vagina at 3cm below the cervix with right-angle forceps, and scrub the vagina successively with 2 pieces of saline gauze
The scrubbed gauze was rinsed with normal saline, and then bagged and sent off for cytological examination. Finally, the vagina was disinfected with iodophor gauze, and then severed under right-angle
3. For the above series of improvement steps, the key technology is to fully scrub and disinfected the vagina after the right-angle clamp is closed, to ensure the tumor-free environment of the vagina
Control Group:The control group received traditional abdominal radical hysterectomy(ARH):
1. The patient was placed in a conventional supine position
2. Firstly, pelvic lymph nodes were removed systematically. The vesico-cervical ligament was removed and the ureter was separate. The principal sacral ligament was removed to the paravaginal area.
3.
Sponsors
Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-60 years old; 2. Preoperative pathological diagnosis of cervical squamous cell carcinoma, adenocarcinoma or adenocarcinoma; 3. Gynecological examination and MRI imaging stage of cervical cancer IA1 (LVSI+) ~IIA2 (FIGO stage 2018); 4. Did not receive any adjuvant chemoradiotherapy before surgery; 5. All patients signed informed consent.
Exclusion criteria
Exclusion criteria: 1. The pathological type is neuroendocrine, clear cell, serous cell or metastatic tumor; 2. The uterus is larger than 3 months of gestation; 3. Pregnant women; 4. Receiving neoadjuvant chemotherapy or radiotherapy before surgery; 5. Life expectancy is less than 6 months; 6. Failure to receive follow-up on time; 7. Patients with systemic serious underlying diseases, immune diseases, mental diseases or other malignant tumors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year and 5-year disease-free survival (DFS);General clinical features; | — |
Secondary
| Measure | Time frame |
|---|---|
| 3-year and 5-year overall survival(OS);recurrence rate;recurrence pattern; | — |
Countries
China
Contacts
Public ContactLi Xuqing
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed